Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 487

1.

Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth.

Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen R, Chang L, Zhang Y, Goto J, Onda H, Chen T, Wang MR, Lu Y, You H, Kwiatkowski D, Zhang H.

Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4129-34. doi: 10.1073/pnas.1014769108. Epub 2011 Feb 15.

2.

Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2.

Iqbal MA, Siddiqui FA, Gupta V, Chattopadhyay S, Gopinath P, Kumar B, Manvati S, Chaman N, Bamezai RN.

Mol Cancer. 2013 Jul 9;12:72. doi: 10.1186/1476-4598-12-72.

3.

Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of rapamycin.

Iqbal MA, Bamezai RN.

PLoS One. 2012;7(5):e36764. doi: 10.1371/journal.pone.0036764. Epub 2012 May 4.

4.

PDK4 protein promotes tumorigenesis through activation of cAMP-response element-binding protein (CREB)-Ras homolog enriched in brain (RHEB)-mTORC1 signaling cascade.

Liu Z, Chen X, Wang Y, Peng H, Wang Y, Jing Y, Zhang H.

J Biol Chem. 2014 Oct 24;289(43):29739-49. doi: 10.1074/jbc.M114.584821. Epub 2014 Aug 27.

5.

Lactate dehydrogenase B is critical for hyperactive mTOR-mediated tumorigenesis.

Zha X, Wang F, Wang Y, He S, Jing Y, Wu X, Zhang H.

Cancer Res. 2011 Jan 1;71(1):13-8. doi: 10.1158/0008-5472.CAN-10-1668.

6.

NFκB up-regulation of glucose transporter 3 is essential for hyperactive mammalian target of rapamycin-induced aerobic glycolysis and tumor growth.

Zha X, Hu Z, Ji S, Jin F, Jiang K, Li C, Zhao P, Tu Z, Chen X, Di L, Zhou H, Zhang H.

Cancer Lett. 2015 Apr 1;359(1):97-106. doi: 10.1016/j.canlet.2015.01.001. Epub 2015 Jan 8.

PMID:
25578782
7.

Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.

Makinoshima H, Takita M, Saruwatari K, Umemura S, Obata Y, Ishii G, Matsumoto S, Sugiyama E, Ochiai A, Abe R, Goto K, Esumi H, Tsuchihara K.

J Biol Chem. 2015 Jul 10;290(28):17495-504. doi: 10.1074/jbc.M115.660498. Epub 2015 May 28.

8.

Pyruvate kinase M2 affects liver cancer cell behavior through up-regulation of HIF-1α and Bcl-xL in culture.

Dong T, Yan Y, Chai H, Chen S, Xiong X, Sun D, Yu Y, Deng L, Cheng F.

Biomed Pharmacother. 2015 Feb;69:277-84. doi: 10.1016/j.biopha.2014.12.010. Epub 2014 Dec 19.

PMID:
25661370
9.

HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer.

David CJ, Chen M, Assanah M, Canoll P, Manley JL.

Nature. 2010 Jan 21;463(7279):364-8. doi: 10.1038/nature08697. Epub 2009 Dec 13.

10.

Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation.

Ye J, Mancuso A, Tong X, Ward PS, Fan J, Rabinowitz JD, Thompson CB.

Proc Natl Acad Sci U S A. 2012 May 1;109(18):6904-9. doi: 10.1073/pnas.1204176109. Epub 2012 Apr 16.

11.

Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression.

Nemazanyy I, Espeillac C, Pende M, Panasyuk G.

Biochem Soc Trans. 2013 Aug;41(4):917-22. doi: 10.1042/BST20130034.

PMID:
23863156
12.

Pyruvate kinase type M2 is upregulated in colorectal cancer and promotes proliferation and migration of colon cancer cells.

Zhou CF, Li XB, Sun H, Zhang B, Han YS, Jiang Y, Zhuang QL, Fang J, Wu GH.

IUBMB Life. 2012 Sep;64(9):775-82. doi: 10.1002/iub.1066. Epub 2012 Jul 18.

13.

MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells.

Kosugi M, Ahmad R, Alam M, Uchida Y, Kufe D.

PLoS One. 2011;6(11):e28234. doi: 10.1371/journal.pone.0028234. Epub 2011 Nov 28.

14.

Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth.

Chiavarina B, Whitaker-Menezes D, Martinez-Outschoorn UE, Witkiewicz AK, Birbe R, Howell A, Pestell RG, Smith J, Daniel R, Sotgia F, Lisanti MP.

Cancer Biol Ther. 2011 Dec 15;12(12):1101-13. doi: 10.4161/cbt.12.12.18703. Epub 2011 Dec 15.

15.

Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells.

Mazurek S.

Int J Biochem Cell Biol. 2011 Jul;43(7):969-80. doi: 10.1016/j.biocel.2010.02.005. Epub 2010 Feb 13. Review.

PMID:
20156581
16.

Pyruvate kinase M2 and cancer: an updated assessment.

Iqbal MA, Gupta V, Gopinath P, Mazurek S, Bamezai RN.

FEBS Lett. 2014 Aug 19;588(16):2685-92. doi: 10.1016/j.febslet.2014.04.011. Epub 2014 Apr 18. Review.

17.

Oleanolic acid suppresses aerobic glycolysis in cancer cells by switching pyruvate kinase type M isoforms.

Liu J, Wu N, Ma L, Liu M, Liu G, Zhang Y, Lin X.

PLoS One. 2014 Mar 13;9(3):e91606. doi: 10.1371/journal.pone.0091606. eCollection 2014.

18.

Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade.

Ma J, Meng Y, Kwiatkowski DJ, Chen X, Peng H, Sun Q, Zha X, Wang F, Wang Y, Jing Y, Zhang S, Chen R, Wang L, Wu E, Cai G, Malinowska-Kolodziej I, Liao Q, Liu Y, Zhao Y, Sun Q, Xu K, Dai J, Han J, Wu L, Zhao RC, Shen H, Zhang H.

J Clin Invest. 2010 Jan;120(1):103-14. doi: 10.1172/JCI37964. Epub 2009 Dec 28.

19.

Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells.

Tamada M, Suematsu M, Saya H.

Clin Cancer Res. 2012 Oct 15;18(20):5554-61. doi: 10.1158/1078-0432.CCR-12-0859. Review.

20.

Anticancer Effects of γ-Tocotrienol Are Associated with a Suppression in Aerobic Glycolysis.

Parajuli P, Tiwari RV, Sylvester PW.

Biol Pharm Bull. 2015;38(9):1352-60. doi: 10.1248/bpb.b15-00306.

Items per page

Supplemental Content

Write to the Help Desk